Anti-Hypertensive Drugs - North America

North America

Highlights

The projected revenue for the Anti-Hypertensive Drugs market in North America is estimated to reach US$12.83bn in 2024.
It is expected to demonstrate an annual growth rate (CAGR 2024-2029) of -0.46%, leading to a market volume of US$12.54bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$12.29bn in 2024.
In North America, there is a growing demand for innovative and personalized anti-hypertensive drugs to effectively manage the high prevalence of hypertension in the region.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Hypertensive Drugs market in North America has been growing steadily in recent years.

Customer preferences: The rising prevalence of hypertension in the region has led to an increased demand for anti-hypertensive drugs. Patients are increasingly seeking drugs that are effective, have minimal side-effects, and are affordable. Additionally, there is a growing preference for combination therapies that can effectively treat hypertension with fewer pills.

Trends in the market: One of the major trends in the anti-hypertensive drugs market in North America is the increasing use of generic drugs. Generic drugs are becoming more popular due to their lower cost, which makes them more affordable for patients. Additionally, there is a growing trend towards the development of fixed-dose combination drugs that combine two or more drugs in a single pill. This trend is driven by the need for more convenient and effective treatments for hypertension.

Local special circumstances: The United States is the largest market for anti-hypertensive drugs in North America. The market is highly regulated, and drug prices are among the highest in the world. This has led to a growing trend towards the importation of drugs from Canada and other countries where drug prices are lower. Additionally, there is a growing trend towards the use of telemedicine to provide remote consultations and prescriptions for patients with hypertension.

Underlying macroeconomic factors: The aging population in North America is a major driver of the growth in the anti-hypertensive drugs market. As people age, they are more likely to develop hypertension, which increases the demand for anti-hypertensive drugs. Additionally, rising healthcare costs and the increasing prevalence of chronic diseases like hypertension are driving the need for more cost-effective and efficient treatments. Technological advancements in the healthcare sector, such as telemedicine and digital health, are also driving the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.